EZH2 Inhibitor Cuts Risk of Progression in Metastatic Prostate Cancer

(MedPage Today) -- A randomized phase II trial presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium found that adding the EZH2 inhibitor mevrometostat to enzalutamide (Xtandi) significantly improved radiographic...